China Pharma Holdings, Inc. announced it has received the Good Manufacturing Practice (GMP) certification and approval from the Chinese State Food and Drug Administration (SFDA) for the production of cephalosporin.

China Pharma has recently completed its facility dedicated to the production of cephalosporin in the tablet and capsule form. The facility was constructed with advanced computer-controlled manufacturing equipment, which provides increased manufacturing efficiencies and reduces production cost. The new facility can produce up to 250 million tablets and 180 million capsules.

Cephalosporin is a class of antibiotics, used in the treatment of infections caused by bacteria. The broad spectrum of activity and safety profile make cephalosporin one of the most widely prescribed class of antimicrobials. In China, antimicrobial sales reach more than $4.8 billion in 2003, according to IMS Health. It is the top selling class of drugs with a growth rate of 20% annually. China Pharma plans to build a separate facility to manufacture the drug in an injectable form.

'We are very pleased that we received the GMP certification for our manufacturing of cephalosporin and the approval from the SFDA for its production. There is a large market opportunity in China for this drug which we feel we are in the position to penetrate,' commented Zhi-lin Li, President and CEO.

Source:佚名